Today, for the first time, an FDA advisory panel voted to open a legal path for BPC-157 — the most sought-after peptide in the world. That's genuinely a milestone. And it's worth understanding exactly what just happened. The panel voted 8-6 to recommend adding BPC-157 to the list of substances licensed compounding pharmacies can prepare under a real prescription. FDA staff had recommended against it. The panel went the other way. Here's why I think that matters, even as a cautious physician. Right now, millions of people are already taking this. They're buying research-grade powder from anonymous overseas sellers, mixing it on a kitchen counter, and injecting it. Over 40% of gray-market samples fail purity testing. No dosing standards. No sterility guarantee. No adverse-event reporting. No physician watching. A vote like today's is the first real step toward moving all of that into daylight — into licensed pharmacies, with quality control, physician oversight, and traceable safety data. That's a genuine win for patient safety, regardless of what you believe about the molecule. And the underlying science is legitimately exciting. BPC-157 is a synthetic peptide modeled on a protective protein found in human gastric juice. Hundreds of animal studies show accelerated tendon and ligament healing, gut protection, anti-inflammatory effects, and angiogenesis — the growth of new blood vessels. The preclinical signal is strong enough that serious researchers keep coming back to it. That's not nothing. That's why the demand exists in the first place. Now the sober part, because you deserve both halves. The published human evidence is still remarkably thin — roughly 30 subjects in the strongest studies, with the longest treatment lasting about two weeks. And the routes actually studied barely overlap with how people use it today. There are no completed randomized controlled trials for the popular uses. Also worth knowing: today's vote is not FDA approval. It's advisory and non-binding. Formal rulemaking takes 12 to 24 months. Nothing changed legally today. My one clinical caution, and it comes from my own field: the same angiogenesis that may heal a tendon is a signal that says grow. Nobody has studied that over years, and nobody has studied it in cancer survivors. Worth a real conversation with your doctor before you assume it's harmless. But here's the encouraging part. A Phase 2 hamstring trial is already underway. A regulated pathway means better product, real prescriptions, and — crucially — actual data collection instead of anecdotes. This is how a gray market becomes medicine: oversight first, then evidence, then answers. Today was a step in that direction. Now let's get the trials done and find out what this thing can really do.